Meet ApplyKite Twin, the application assistant that learns with you

Meet your Twin, it learns with you

Your Twin learns with you

Launch week codes:30% off annual Pro20% off monthly Pro

Ends in00h00m00s

Carmine Valenza

European Institute of Oncology

Italy

Research Interests

Explore related searches

Professors in Italy Professors in Immunology Immunology professors in Italy

Articles (20)

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2026

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (14)

Fabio Puglisi

Head of the Unit of Medical Oncology and Cancer Prevention

ITALY

View details

Pietro De Placido

Harvard University

UNITED STATES

View details

Eleonora Nicolò

Weill Cornell Medicine

UNITED STATES

View details

Paolo Veronesi

Docenti

University of Milan

ITALY

View details

Caterina Sposetti

Dana-Farber Cancer Institute

UNITED STATES

View details

Laura Boldrini

European Institute of Oncology

ITALY

View details

Paolo Tarantino

Dana-Farber Cancer Institute

UNITED STATES

View details

Giuseppe Curigliano

European Institute of Oncology

ITALY

View details

Joaquin Mateo

Group Leader

Vall d´Hebron Institute of Oncology

SPAIN

View details

Luca Boscolo Bielo

European Institute of Oncology

ITALY

View details

MONICA ARNEDOS

Institut Bergonié

FRANCE

View details

Chiara Cremolini

University Hospital of Pisa

ITALY

View details

Yue Zheng

Dana-Farber Cancer Institute

UNITED STATES

View details

Ann Partridge

Vice Chair

Dana-Farber Cancer Institute

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Carmine Valenza

Research Interests

Explore related searches

Articles (20)

Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor–Positive Breast Cancer: A Cohort Study

Measurement of ovarian reserve to tailor systemic therapy decisions: future potential or ready for primetime?

Second ipsilateral locoregional recurrence in patients with hormone receptor-positive, HER2-negative breast cancer: a cohort study

Bridging the Gap: Advancing First-Line Therapy for Patients With Metastatic Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

Inadequate ovarian function suppression and endocrine therapy manipulations in premenopausal patients with early breast cancer on adjuvant LHRH agonist and aromatase inhibitor: a cohort study

Role of Social Media for Medical Oncologists and Medical Oncology Fellows (SMARTY): An Italian Cross-Sectional Study

Circulating tumor DNA clearance as a predictive biomarker of pathologic complete response in patients with solid tumors treated with neoadjuvant immune checkpoint inhibitors: a systematic review and meta-analysis

Breast surgery and systemic treatment continuation for patients with de novo metastatic breast cancer and locoregional oligoprogression: a cohort study

Do all patients with early breast cancer meeting the NATALEE criteria benefit from adjuvant ribociclib?

Positioning oral selective estrogen receptor degraders in patients with metastatic breast cancer

Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms

Elacestrant in ESR1-mutant, endocrine-responsive metastatic breast cancer: should health authorities consider post hoc data to inform priority access?

Biomarkers for Antibody–Drug Conjugates in Solid Tumors

Primary malignant phyllodes tumors of the breast: A retrospective analysis from a referral center

Optimizing Postneoadjuvant Treatment in Patients With Early Breast Cancer Achieving Pathologic Complete Response

Circulating tumor DNA in patients with locally advanced rectal cancer treated with multimodal treatment

Resistance to Antibody-Drug Conjugates Targeting HER2 in Breast Cancer: Molecular Landscape and Future Challenges

Platinum-based chemotherapy and PARP inhibitors for patients with a germline<i> BRCA</i> pathogenic variant and advanced breast cancer (LATER-BC): retrospective multicentric analysis of post-progression treatments

The immunogram of inflammatory breast cancer

Multimodal treatment for resectable neuroendocrine carcinoma of the cervix

Collaborators (14)

Fabio Puglisi

Pietro De Placido

Eleonora Nicolò

Paolo Veronesi

Caterina Sposetti

Laura Boldrini

Paolo Tarantino

Giuseppe Curigliano

Joaquin Mateo

Luca Boscolo Bielo

MONICA ARNEDOS

Chiara Cremolini

Yue Zheng

Ann Partridge

Make your next move.